Regarding this, XIAP has been reported to confer acquired resistance to GW583340 (an EGFR/HER2 inhibitor) in inflammatory breast cancer cell lines, SUM190 and SUM149, and down-regulation of XIAP by a small-molecule inhibitor, embelin, which inhibits the XIAP/pro-caspase-9 interaction, decreases viability of these cells 32. The gene discussed is CASP9; the disease is inflammatory breast carcinoma.